Symptoms of dyspnoea · stable COPD
Triple therapy probably leads to higher symptom score TDI, ≥ 1‐unit increase (lower scores indicate worse… compared with LABA/LAMA combination (moderate certainty).
1 finding from 1 review
Change in baseline trough FEV1 · stable COPD
Triple therapy may leads to higher lung function, change in trough FEV1 (mL) compared with LABA/LAMA combination (low certainty).
1 finding from 1 review
Mortality (all‐cause) · stable COPD
Triple therapy may leads to lower mortality (all‐cause) compared with LABA/LAMA combination (low certainty).
1 finding from 1 review
Aggression · adults with antisocial personality disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Reconviction · adults with antisocial personality disorder
It is very uncertain whether schema therapy changes reconviction Assessed by: number of participants documented to have… compared with treatment‐as‐usual (very low certainty).
1 finding from 1 review
Global state/functioning · adults with antisocial personality disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Social functioning Assessed by: mean number of days until unsupervised leave grantedb Timing of assessment: over the 3 years · adults with antisocial personality disorder
1 finding from 1 review
Remission · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in remission (number of patients with remission) compared with standard therapy with placebo (low certainty).
1 finding from 1 review
RR 0.97 [0.89, 1.07]
Studies not reported
Low
Durable remission · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in durable remission compared with standard therapy with placebo (low certainty).
1 finding from 1 review
RR 0.93 [0.77, 1.11]
Studies not reported
Low
Major relapse · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in major relapse compared with standard therapy with placebo (low certainty).
1 finding from 1 review
RR 2.94 [0.12, 70.67]
Studies not reported
Low
Disease flare · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in disease flare compared with standard therapy with placebo (moderate certainty).
1 finding from 1 review
RR 0.98 [0.76, 1.27]
Studies not reported
Moderate
Any adverse event · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in any adverse event compared with standard therapy with placebo (low certainty).
1 finding from 1 review
RR 1.12 [0.97, 1.29]
Studies not reported
Low
Any severe or serious AE (grade 3, 4 or 5) · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in any severe or serious AE (grade 3, 4 or 5) compared with standard therapy with placebo (low certainty).
1 finding from 1 review
RR 1 [0.8, 1.27]
Studies not reported
Low
Withdrawals due to adverse events · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy may leads to higher any withdrawals due to AE compared with standard therapy with placebo (low certainty).
1 finding from 1 review
RR 2.66 [1.07, 6.59]
Studies not reported
Low
MortalityNumber of participants: 285(2 RCTs) WGET 2005 · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in mortalityNumber of participants: 285(2 RCTs) WGET 2005 compared with standard therapy with placebo (low certainty).
1 finding from 1 review
Outcomes · obsessive compulsive disorder (OCD) in individuals with autism spectrum disorder (ASD)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment efficacy (change in OCD score), end of treatment. Measured by Y‐BOCs Score · obsessive compulsive disorder (OCD) in individuals with autism spectrum disorder (ASD)
1 finding from 1 review
Dropout · obsessive compulsive disorder (OCD) in individuals with autism spectrum disorder (ASD)
Cognitive behavioural therapy showed no clear difference in total number of dropouts, end of treatment compared with anxiety management (low certainty).
1 finding from 1 review
Quality of life, end of treatment Measured by WSAS Score · obsessive compulsive disorder (OCD) in individuals with autism spectrum disorder (ASD)
1 finding from 1 review
Depressive symptoms · obsessive compulsive disorder (OCD) in individuals with autism spectrum disorder (ASD)
1 finding from 1 review